TLL-018

DRUG5 trials

Sponsors

Hangzhou Highlightll Pharmaceutical Co., Ltd

Conditions

Chronic Spontaneous Urticaria (CSU)Rheumatoid ArthritisRheumatoid Arthritis (RA)

Phase 1

A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines

Not yet recruitingNCT07665996

Hangzhou Highlightll Pharmaceutical Co., LtdChronic Spontaneous Urticaria (CSU)

Start: 2026-08-15End: 2027-12-31Target: 36Updated: 2026-08-24

Phase 2

The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

CompletedNCT05133297

Hangzhou Highlightll Pharmaceutical Co., LtdRheumatoid Arthritis

Start: 2022-02-16End: 2023-05-30Updated: 2023-09-05

TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs

Not yet recruitingNCT07748728

Hangzhou Highlightll Pharmaceutical Co., LtdRheumatoid Arthritis (RA)

Start: 2026-08-14End: 2027-12-31Target: 90Updated: 2026-08-06

Phase 3

A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs

Active, not recruitingNCT06020144

Hangzhou Highlightll Pharmaceutical Co., LtdRheumatoid Arthritis

Start: 2023-11-15End: 2026-12-31Updated: 2026-05-22

A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis

RecruitingNCT06887127

Hangzhou Highlightll Pharmaceutical Co., LtdRheumatoid Arthritis

Start: 2025-03-10End: 2027-12-31Target: 350Updated: 2026-05-20

Related Papers

Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Artrite Reumatoide

Epidemiologia e Serviços de Saúde2025-01-01